Trial Search Results

JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Tofacitinib 5 mg
  • Drug: Placebo to match Tofacitinib


Phase 2


Inclusion Criteria:

   - Patients undergoing esophagectomy

Exclusion Criteria:

   - Patients with more than mild pulmonary dysfunction

   - Patients with any neuromuscular disease that might compromise diaphragm function

   - Patients with abnormal liver or kidney function

   - Patients taking any immunosuppressant medication (including prednisone) or antifungal

   - History of tuberculosis

   - Weight loss of >5% of body weight over previous 6 months

   - Pregnancy

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Study Team